Multinational pharmaceutical companies, such as MSD, Pfizer, Roche and AZ, are about to compete over immune antibodies

As domestic Phase 3 clinical trials have actively been made for immune antibodies indicated as the new cancer treatment, a new heated competition is expected in the antibody market.

While MSD and Ono have acquired approvals for anti-PD-L1 immune antibodies, respective ‘Keytruda (generic name: pembrolizumab)’ and ‘Opdivo (generic name: nivolumab),’ other multinational pharmaceutical products, s...